

# INTRODUCTION TO PHARMACOLOGY

---

- Marei is a 57-years-old farmer. On several visits over a period of a year you note his blood pressure is **142/97**
- He has a **history of smoking & has chronic bronchitis** He also has **elevated lipid and cholesterol levels**
- You wish to begin antihypertensive therapy
- Two of the potential choices are **prazosin**, which is a **competitive alpha-receptor blocker**, and **propranolol**, which is a **competitive beta-receptor antagonist**

# Molecular Aspects of Drug Actions

- Pharmacology is the science dealing with drug actions

Drug + Molecular Target



Pharmacologic Effect




Therapeutic Response  
And Adverse effects

## Effect of Salbutamol

Molecular	→	Beta <sub>2</sub> -AR agonist
Cellular	→	Bronchiolar SM Relaxation
Tissue	→	Bronchodilation
System	→	Relief of breathing

# Pharmacokinetics (PK) and Pharmacodynamics (PD)

---



# FOUR MOLECULAR PROTEIN TARGETS FOR DRUGS

---

I. **Ion Channels**

II. **Enzymes**

III. **Carrier molecules**

IV. **Receptors**

➤ **Non drug-target model:**

**A fifth class of drug act on NO  
molecular target**

# Ion Channels

**B**


## ION CHANNELS

Blockers



Permeation  
blocked

Modulators



Increased or  
decreased  
opening probability

# Ion Channels

---

- Drugs can **DIRECTLY** bind to channel proteins leading to alteration of its function
- **First:** physical blockade of the channel by the drug molecule
- Example: blocking of neuronal voltage-gated  $\text{Na}^+$  channels by local anesthetics and inhibition of  $\text{Na}^+$  entry in renal tubules by amiloride diuretic

# Ion Channels

---

- *Second mode* is modulation of channel function by drugs that bind to accessory sites on the channel protein (**allosteric modulators**)
- Example: The blocking effect of dihydropyridines on voltage-gated calcium channels

# ENZYMES

## C ENZYMES

Inhibitor



Normal reaction  
inhibited

False  
substrate



Abnormal  
metabolite produced

Pro-drug



Active drug produced



# ENZYMES

- ❑ *Competitive inhibitor of the enzyme* by being a substrate analogue

- ❑ Examples:

- Irreversible inhibition of **cyclo-oxygenase** by **aspirin**
- reversible inhibition of cholinesterase by neostigmine

- ❑ The drug acts as *true/false substrate*


- ❑ Examples:

- **L-DOPA converted into dopamine**
- Hemicholinium targeting choline acetyltransferase


# CARRIERS

## D TRANSPORTERS

Normal  
transport



Inhibitor



Transport  
blocked

False  
substrate



Abnormal compound  
accumulated

# CARRIER MOLECULES


---

- Carrier protein molecules function to **transport ions & small organic molecules** (too polar to penetrate) across cell membranes
- They possess a recognition site that confers specificity for a particular carried agent
- Such recognition sites can be targets for drugs where they block the transport system
- An example is the inhibition of **cardiac Na<sup>+</sup>K<sup>+</sup>-ATPase** by **cardiac glycosides**

# RECEPTORS

## A RECEPTORS

Agonist



Antagonist



No effect  
Endogenous mediators blocked

# RECEPTORS

---

- Receptors are **cellular macromolecular proteins** located either in the cell membrane or less frequently in the cytoplasm
- They have **specific recognition sites** that bind selectively with a structurally-related group of synthetic drugs and endogenous mediators (ligands)

# Non Drug-Molecular Target Model

---

- Few drugs act through non-receptor (non-target)-mediated mechanisms
- Mannitol is a sugar that acts as a diuretic
- ✓ It has NO molecular target in the nephron
- ✓ Mannitol acts by creating an increased intraluminal osmotic pressure
- Antacids act nonspecifically by absorbing or chemically neutralizing gastric acid

# *Receptor Classification*

---

- **Receptor classification** relies upon both **molecular structure** and **pharmacological functional aspects**
- The ***operational (functional)*** aspects of receptors involve both **recognition** as well as **transduction characteristics**

# RECEPTOR STRUCTURE


---

- Membrane receptors are usually composed of three parts:
  - one or more than one **hydrophobic membrane-spanning  $\alpha$ -helical segment**
  - the **extracellular ligand-binding domain**
  - the **intracellular transduction domain**



# ***CLASS 1: TRANSMITTER-GATED ION CHANNELS (IONOTROPIC RECEPTORS)***


- The receptor is an **integral part of an ion channel**
- Opening and closing of the ion channel is controlled by agonist binding, mostly fast neurotransmitters
- Examples: nicotinic ACh (nACh) receptors, 5-HT<sub>3</sub> & the GABA<sub>A</sub> receptors



# ***Class 1: Ionotropic Receptors***


## ***Structure***

- The prototype nACh receptor is a **pentamer protein** ( $\alpha_2\beta\gamma\delta$ ), each of four **hydrophobic membrane-spanning helices**
- Each subunit bring one membrane-inserted segment towards the centre of the structure creating the channel pore




# Class 2: G-protein-Coupled (Metabotropic) Receptors

- Receptors are linked to **GTP-binding protein (G-protein)**
- G-protein controls the activity of an **effector protein**; a membrane enzyme or an ion channel
- Activation/inhibition of the effector enzyme increase/decrease the release of a diffusible **second messenger** such as cAMP or IP<sub>3</sub>



# Class 2: G-Protein-Coupled Receptors Structure

- A single 400-500-amino acid polypeptide chain as seven transmembrane  $\alpha$ -hydrophobic helices
- Three regions exist the extracellular amino terminus, the intracellular carboxy terminus & a long cytoplasmic loop responsible for interaction with G-protein
- Agonist-binding usually occurs on a hydrophilic domain lying among the helices or on N-terminus



# Major Types of G-Proteins

---

G-Protein	Actions
<b>G-stimulatory (<math>G_s</math>)</b>	Activates $Ca^{2+}$ channels/ adenylyl cyclase
<b>G-inhibitory (<math>G_i</math>)</b>	Activates $K^+$ channels/ Inhibits adenylyl cyclase
<b><math>G_0</math></b>	Inhibits $Ca^{2+}$ channels
<b><math>G_q</math></b>	Activates phospholipase C
<b><math>G_{12/13}</math></b>	Interactions with different ion trasnporters

# ***Targets for G-proteins***

---

- **The adenylate cyclase/c-AMP system/PKA cascade**
- **The phospholipase C (PLC)/ inositol triphosphate (IP<sub>3</sub>)-Ca<sup>2+</sup> release/DAG-PKC system**
- **G-protein direct regulation of ion channel, e.g., muscarinic ACh receptors stimulate cardiac potassium channels**


## ***Class 3: Enzyme-associated Receptors***

---

- The receptors functions both as recognition site (receptor) as well as an enzyme usually on the intracellular side, activated upon agonist binding
- They are two main groups
  - (1) *tyrosine-kinase-linked receptors* such as receptors for insulin, growth factors and many cytokines,
  - (2) *guanylate cyclase-coupled receptors* for atrial natriuretic peptide (ANP)


## ***Class 3: Enzyme-associated Receptors***

- Receptors consist of a single polypeptide chain of 3 parts
  - One hydrophobic *membrane-inserted segment*
  - Extracellular agonist-binding domain
  - Intracellular catalytic (enzyme) domain





# ***Class 3: Enzyme-associated Receptors***



- ***tyrosine-kinase receptors*** for insulin and cytokines
- **Guanylate cyclase receptors** for ANP


## ***Class 4: Gene Transcription- Regulating Receptor***

---

- **This is the only intracellular cytoplasmic protein receptors, **NO membrane segments****
- **Ligands are lipophilic molecules that can readily cross cell membrane like slow acting hormones including steroid and thyroid hormones**


# ***Class 4: Gene Transcription-Regulating Receptor***

- A single polypeptide chain located in the **cytoplasm** of 3 main segments
  - ***DNA binding domain***
  - ***Agonist binding domain*** (C-terminus)
  - ***Gene-transcription domain*** (N-terminus) bound to hsp90 protein



# ***Class 4: Gene Transcription-Regulating Receptor***

- Upon receptor-ligand binding, the hsp90 protein is released, uncovering the DNA binding gene-transcription domains
- Followed by stimulation or suppression of a specific m.RNA-protein synthesis cascade
- Glucocorticoids inhibit the transcription of the gene responsible for the synthesis of cyclo-oxygenase-2 (COX-2)



# The Four Main Classes of Receptors

